Trump’s Prescription Drug Price Reform: What It Means for Americans and the Pharma Industry

In a move coinciding with eased tariffs on China, President Donald Trump signed an executive order aimed at reducing prescription drug prices in the U.S., directing officials to align domestic prices with those paid abroad. The order also encourages direct-to-consumer sales and explores importing lower-cost medications from overseas. While Trump claimed the action would slash prices by up to 80%, experts and investors anticipate a modest impact, noting that enforcement details remain unclear and negotiations are likely to be prolonged. Drawing parallels to his trade strategy, the effort reflects tough rhetoric with potentially muted financial consequences for the pharmaceutical sector—prompting some investors to view it as a buying opportunity in a historically high-cost, innovation-subsidizing market.

Trump’s Bold Plan to Slash Drug Costs

President Trump signed an executive order on May 12, 2025, directing the U.S. Department of Health and Human Services (HHS) to align U.S. drug prices with those in other wealthy nations. The order mandates HHS Secretary Robert F. Kennedy Jr. to set price targets for pharmaceutical companies within 30 days. If companies fail to comply, the administration may enforce a “Most Favored Nation” (MFN) model, capping U.S. prices at the lowest rates abroad. Trump claims this could reduce prices by 59% to 90%, citing drugs like Wegovy, which costs $1,349 monthly in the U.S. but $130 in the UK.

The plan extends beyond Medicare and Medicaid, which cover two-fifths of U.S. drug sales, to include private insurance markets. It also encourages direct-to-consumer sales, bypassing pharmacy benefit managers (PBMs) like Cigna and CVS, which take up to 50% of drug spending. This ambitious scope sets it apart from Trump’s first-term MFN attempt, which courts blocked for procedural reasons.

Why U.S. Drug Prices Soar

The U.S. healthcare system’s complexity fuels high drug costs. Unlike centralized systems in the UK or EU, where governments negotiate blanket rates, U.S. prices are set through fragmented private insurance, employer subsidies, and public programs like Medicare. A 2021 U.S. Government Accounting Office study found U.S. drug prices 256% higher than in 32 other countries. For example, Ozempic costs $1,300 in New York but $88 in London. Both parties have targeted these costs, with Biden’s Inflation Reduction Act enabling Medicare to negotiate prices for some drugs since 2024.

Pharmaceutical lobbying, one of Washington’s strongest, has long stalled reform. Trump blames these lobbies for past failures, vowing to end U.S. subsidization of global drug innovation. However, his proposed tariffs on imported drugs could paradoxically raise costs, complicating the push for affordability.

Unclear Enforcement and Global Price Ties Spark Legal Risks, Industry Pushback, and Innovation Concerns in Trump’s Drug Pricing Order

The executive order lacks clear enforcement mechanisms, raising doubts about its impact. The MFN model requires drugmakers to match the lowest global prices, but defining “unreasonable” pricing remains vague. Companies could manipulate prices abroad, inflate list prices while offering rebates, or withdraw drugs from low-price markets to avoid U.S. benchmarks. Legal challenges are likely, as seen in 2020 when courts halted Trump’s first MFN attempt. The pharmaceutical industry, led by groups like PhRMA, warns that price caps could cut research funding, with companies planning $200 billion in U.S. investments.

Analysts at UBS predict a 6% profit hit for European drugmakers like AstraZeneca and Novo Nordisk, and a 10% drop for U.S. firms like Pfizer and Bristol Myers Squibb if MFN pricing applies to the top 50 drugs. However, firms like GSK and Sanofi may face less impact. The industry argues that price controls could stifle innovation, though some experts suggest alternative funding models, like cash prizes for new cures.

Market Reactions Signal Skepticism

Drugmakers’ stocks, including Pfizer, Eli Lilly, and GSK, dipped after Trump’s announcement but quickly recovered, suggesting investors see limited immediate impact. The NYSE Arca Pharmaceutical Index trades at 13.6 times next year’s earnings, a 10% discount to its 10-year average and 30% below the S&P 500’s 20.5 multiple. This reflects priced-in risks, making pharma stocks potentially attractive for long-term investors despite uncertainties.

Trump’s history of bold rhetoric often leads to modest outcomes. His recent U.K. trade deal, valued at hundreds of millions, mirrors the likely trajectory for drug pricing: negotiated concessions, such as 20% cuts on expiring patents, rather than sweeping reform. Analyst Chris Meekins of Raymond James calls the order “not a material event,” citing Trump’s first-term pattern of “all bark, no bite.”

Potential Impacts on Consumers and Industry

If successful, the plan could lower costs for millions, especially for high-demand drugs like GLP-1s (e.g., Wegovy, Ozempic). Polls show drug costs are a top concern for Americans, and even small reductions would resonate. However, experts doubt lasting change, noting Trump’s shifting priorities. Drugmakers may resist by limiting supply in low-price countries or challenging the order in court, as PhRMA and the Biotechnology Innovation Organization call it a “bad deal” for patients.

The plan’s alignment with Kennedy’s “Make America Healthy Again” agenda is unclear, given his focus on diet over pharmaceuticals. Meanwhile, Trump’s tariff threats and merger-blocking powers add pressure, but companies like Novo Nordisk and AstraZeneca signal willingness to negotiate, potentially softening the blow.

What Lies Ahead for Drug Pricing

The executive order marks a bold step, but its success hinges on negotiations and legal battles. The administration’s push for transparency and direct sales could disrupt PBMs, potentially lowering costs. Yet, without Congressional backing, as seen with Biden’s legislative approach, the plan faces hurdles. For now, the pharmaceutical industry braces for impact, while consumers await tangible relief in a system where prices remain stubbornly high.

Author

Bernice Lottering